Member Info for Retireby40

Yep the 3 200k trades clearly Heights’ sells. As mentioned they won’t wanna put too much pressure on the share price and will want 120p or so. They will be cleared soon enough and then we will have AGM update, next cohort etc so no worries.

HC won’t wanna out too much pressure on the sales price and have a quarter to sell them which is fewer than 50k/day. When the 200k went through the spread quickly moved back up. Let’s see what today brings but I strongly suspect blue.

Russell because the sell was cleared. Look at the buys minutes before, they’re higher. It’s a worked sell. I mean look at the day’s trading. Surely this isn’t difficult?!

Same as yesterday. Not a coincidence Heights just converted and good to clear some. Upwards tomo.

It’s obviously a sell. Clear as day. Look at today’s trading and how many were below? The buys just before were higher FFS. A worked well and all good.

It’s a worked sell 100%. The buys before were lower and few trades were lower today. A heights sell for sure. Good news and we’ll move back up.

https://twitter.com/oliver__curtis/status/1651496035074678785?s=46&t=7RwCqYFMh4LrAUw4nqZE7A

As someone who has initiated Clinical Trial sites and played an active role in the recruitment of patients, I think the #AVCT RNS today is significant.
Or rather the timing of today’s RNS is significant

Avacta reported the MSK Cancer Centre had been opened on 5th April.
While perfectly timed for the 5th dosing cohort…
This is only 3 weeks prior to the notification today that the first patient at the MSK Cancer Centre had been dosed
In my experience, Phase I trials are notoriously difficult to recruit for due to extensive inclusion/exclusion criteria.
Once a patient is identified, the hospital must move quickly to screen the patient.

Screening can be between 1 - 28 days depending on the study.
It’s reasonable to assume 7 days for AVA6000 as the screening assessments are largely blood testing, vitals and patient medical history
But an investigator cannot begin these assessments until the patient signs initial consent
And a patient cannot sign the initial consent until a site is activated
Investigators will generally wait for patient referrals through MDT meetings/clinics
But a good investigator will know the medical history and thus eligibility of all the patients they see
They will be actively spreading word of the trial throughout the hospital

In my experience, dosing a patient after 3 weeks in a Phase I trial shows one key thing:

A VERY committed investigator
And a very committed investigator will believe the treatment they provide to their patients will bring great benefit

Stanley, that’s the nature of the space. Money needed to take drugs through trials. Look at the cash burn, their operating cash burn actually reduced. They have cash until back end of next year at the least. So cash is fine and as RAH and others have said Avacta and any companies in the data room will have a lot of data and on efficacy come H1 next year. Assuming the drug continues to perform as it has been raising money or more likely achieving licensing deals etc won’t be an issue.

Cash will be sufficient until end of next year or early 2025.

Unless Dox miraculously changes its structure/properties it will behave how it’s always behaved and are clearly massively de-risked now a scientific point of view. Mechanism of action proven in various animal models for 2 different molecules as well as one proven in-human. Hopefully the FY RNS provides some meat on the bone from a commercial timeline etc and the market will belatedly wake up!

Cheers for your research RAH

Dox detected in just 1 out of 6 biopsies. I remember now. Thanks

Hi RAH, out of interest did they measure the amount of Dox in tumour/plasma 24 hours after the injection?

Bella, wow. The 500 excess deaths per week are due to patients not getting the emergency care they need in time and nothing to do with strikes/doctors. It’s underfunding. 13 years ago the NHS was voted number 1 by its peers in a league table and it’s now Rock bottom.

Anyway, am looking forward to the next few weeks, poster, poster explainer video (including 6000 data), FY results and outlook, Q&A and cash at Dec 31 of around £40m.

Actually assuming launch is continuing to sell covid LFTs and at s handsome margin the more they sell the more cash generated and slightly less cash burn so it all helps.

They’re at a diagnostics event this weekend. Both divisions hopefully busy and generating value.

Their top 8 own over 60% of the business. Surely they will want to see its potential fulfilled and not lose their investments. Providing money for growth at a premium okay to major dilution but money is needed as the sector in its infancy so taking time to grow but on many a radar and will feature in more and more marketing budgets. A shame. Valued at less than cash and great IP too. They are the innovators here and have the impressive clients, partners and clearly need more time.

5 sites according to the link posted on here!

Yes but most of the institutions are holding shares for retail holders in nominee accounts.

And remember biopsies are mandatory which is great. I suspect AS is hopeful the regulators will rubber stamp the new design before FY update.

It needs numbers in order to be statistically significant.

Hard to buy and sells above mid which is good news. MMs want shares. Always positive when MMs pay above and offer fixed for large quantities.

I’ve said this before but I find it odd when people cry manipulation when MMs sell below mid so our buys look like sells. Better for us when other way around.

Sells showing as buys which to me is positive as MMs happy to pay above mid. Good to see. Hence I can never get when many moan that their buy is showing as a sell. Anyway, MMs keen for shares.